In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Acorda Therapeutics (ACOR), with a price target of $30. The company’s shares opened today at $16.50, close to its 52-week low of $12.86.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 3.5% and a 41.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
Currently, the analyst consensus on Acorda Therapeutics is a Hold with an average price target of $24.17, implying a 46.5% upside from current levels. In a report issued on January 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $33 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $36.35 and a one-year low of $12.86. Currently, Acorda Therapeutics has an average volume of 820.1K.
Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules.
